Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Recipient : Formycon
Deal Size : Undisclosed
Deal Type : Partnership
Horus Pharma Becomes Additional Commercialization Partner for Formycon's Eylea Biosimilar
Details : The partnership aims for the commercialization of Formycon's Eylea biosimilar FYB203, under the brand name Baiama, in selected European countries.
Product Name : Baiama
Product Type : Protein
Upfront Cash : Undisclosed
September 17, 2025
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Recipient : Formycon
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Fluocinolone Acetonide
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Alimera Sciences
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Alimera and Horus have agreed to increase the commercialization efforts for ILUVIEN (fluocinolone acetonide) for both diabetic macular edema (DME) and non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in Euro...
Product Name : Iluvien
Product Type : Steroid
Upfront Cash : Undisclosed
April 03, 2023
Lead Product(s) : Fluocinolone Acetonide
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Alimera Sciences
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Barcimiant
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Genuine Research Center, Egypt
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Barcimiant is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 16, 2021
Lead Product(s) : Barcimiant
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Genuine Research Center, Egypt
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rivaroxaban
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Genuine Research Center, Egypt
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rivaroxaban is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 06, 2017
Lead Product(s) : Rivaroxaban
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Genuine Research Center, Egypt
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
